0001562180-20-000898.txt : 20200205
0001562180-20-000898.hdr.sgml : 20200205
20200205172910
ACCESSION NUMBER: 0001562180-20-000898
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200203
FILED AS OF DATE: 20200205
DATE AS OF CHANGE: 20200205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Binney Robert H Jr
CENTRAL INDEX KEY: 0001614476
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36545
FILM NUMBER: 20579882
MAIL ADDRESS:
STREET 1: 1555 ADAMS DRIVE
STREET 2: C/O INTERSECT ENT, INC.
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intersect ENT, Inc.
CENTRAL INDEX KEY: 0001271214
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 200280837
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1555 ADAMS DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650-641-2100
MAIL ADDRESS:
STREET 1: 1555 ADAMS DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER COMPANY:
FORMER CONFORMED NAME: SINEXUS INC
DATE OF NAME CHANGE: 20031124
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2020-02-03
false
0001271214
Intersect ENT, Inc.
XENT
0001614476
Binney Robert H Jr
C/O INTERSECT ENT, INC.
1555 ADAMS DRIVE
MENLO PARK
CA
94025
false
true
false
false
Chief Commercial Officer
Common Stock
2020-02-03
4
A
false
11040.00
0.00
A
27292.00
D
Common Stock
2020-02-03
4
A
false
11040.00
0.00
A
38332.00
D
Stock Options (Right to buy)
26.18
2020-02-03
4
A
false
21870.00
0.00
A
2030-02-03
Common Stock
21870.00
21870.00
D
Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units shall vest on the third anniversary from the date of grant provided that certain 30-day trailing average stock price (the "Average Closing Price") targets are achieved at any time during the three year period following the date of grant. 33 1/3%, 66 2/3% or 100% of the shares will vest if the Average Closing Price equals or exceeds specific stock price targets.
Includes 18,040 restricted stock units, of which 11,040 are performance based.
Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest in three equal annual installments commencing one year after the grant date.
Includes 29,080 restricted stock units, of which 11,040 are performance based.
The vesting commencement date of the option is February 3, 2020. 1/8th of the shares subject to the option shall vest on August 3, 2020 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months.
/s/ David A. Lehman, Attorney-in-Fact for Binney Robert H Jr
2020-02-05
EX-24
2
poabinney.txt
POA-BINNEY
POWER OF ATTORNEY
Know all by these present that the undersigned hereby constitutes
and appoints each of LISA D. EARNHARDT,
JERYL L. HILLEMAN, DAVID A. LEHMAN and MATTHEW B. HEMINGTON,
signing individually,
the undersigneds true and lawful
attorneys-in fact and agents to
(1) execute for and on behalf of the undersigned, in the undersigneds
capacity as an officer, director or beneficial
owner of more than 10% of a registered class of
securities of Intersect ENT Inc. (the Company)
(a) Forms 3, 4 and 5 (including any amendments thereto) in accordance with
Section 16(a) of the
Securities Exchange Act of 1934, as amended (the Exchange Act)
and the rules thereunder and a
b) Form ID, Uniform Application for Access Codes to File on EDGAR
(2) do and perform any and all acts for and on behalf of the undersigned
that may be necessary or
desirable to execute such Forms 3, 4 or 5 or Form ID (including any
amendments thereto
and timely file such forms with the United States Securities and
Exchange Commission
and any stock exchange or similar authority and
(3) take any other action of any nature whatsoever in connection with
the foregoing
which, in the opinion of such attorney-in-fact,
may be of benefit, in the best interest of, or legally required
by, the undersigned,
it being understood that the documents
executed by such attorney-in-fact on behalf of the undersigned
pursuant to this
Power of Attorney
Attorney shall be in such form and shall contain such terms and
conditions as
such attorney-in-fact
may approve in such attorney-in-facts discretion.
The undersigned hereby grants to each such attorney-in-fact full
power and authority
to do and
perform any and every act and thing whatsoever requisite, necessary
or proper
to be done in the
exercise of any of the rights and powers herein granted, as fully
to all intents
and purposes as the
undersigned might or could do if personally present, with full
power of substitution or revocation, hereby ratifying and confirming
all that such
attorney-in-fact, or
such attorney-in-facts substitute or substitutes,
shall lawfully do or cause to be done by virtue of this power of
attorney and the
rights and powers
herein granted. The undersigned acknowledges that the foregoing
attorneys-in-fact,
in serving in such
capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigneds responsibilities
to comply with
Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until
the earliest to occur
of (a) the
undersigned is no longer required to file Forms 3, 4 and 5 with respect
to the undersigneds
holdings of
and transactions in securities issued by the Company,
(b) revocation by the undersigned in a signed writing delivered
to the foregoing
attorneys-in-fact or (c)
as to any attorney-in-fact individually, until such attorney-in-fact
is no longer
employed by the Company
or Cooley LLP.
IN WITNESS WHEREOF the undersigned has caused this Power of
Attorney to be
executed as of January 18, 2019.
/s/ Robert H. Binney
Robert H. Binney